A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

with CF, eligible if change in FEV 1 ≥10% or sweat chloride decreased by at least 15 mEq/L at day 15 and week 8 Age ≥12 years Homozygous F508del Part 1 Ivacaftor (VX-770) 150 mg twice daily (n ...

Some approved CFTR modulators for cystic fibrosis include: a triple combination medication of elexacaftor, tezacaftor, and ivacaftor that could help up to 90% of people with cystic fibrosis ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Vertex has launched the next phase of its plan for the cystic fibrosis market ... The new triple is based on ivacaftor and tezacaftor – which both feature in Vertex’ two-drug combinations ...

Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to < 12 years and less than 30 kg: morning dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...

At three follow-up visits within 6 months, reports of neuropsychological side effects rose or stayed stable among patients with cystic fibrosis receiving elexacaftor ...

Vertex’s Orkambi (lumacaftor+ivacaftor) cystic fibrosis drug is to be reimbursed in Australia’s publicly funded health system after it was cleared by a cost-effectiveness committee.

Lupin receives USFDA approval for its generic version of Ivacaftor oral granules, a treatment for cystic fibrosis. The approval marks a significant step for Lupin in the US market.

Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system, leading to severe respiratory and nutritional challenges. Recent research has focused on ...